Alkermes plc (NASDAQ: ALKS) closed the day trading at $26.78 down -1.94% from the previous closing price of $27.31. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 1345218 shares were traded. ALKS stock price reached its highest trading level at $27.47 during the session, while it also had its lowest trading level at $26.75.
Ratios:
For a better understanding of ALKS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.66. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on March 19, 2024, initiated with a Outperform rating and assigned the stock a target price of $37.
On February 20, 2024, UBS Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Nichols Christian Todd sold 10,417 shares for $28.10 per share. The transaction valued at 292,740 led to the insider holds 65,911 shares of the business.
Parisi Samuel Joseph sold 2,559 shares of ALKS for $75,874 on Feb 27 ’24. The VP, Finance (Interim PAO) now owns 7,717 shares after completing the transaction at $29.65 per share. On Feb 15 ’24, another insider, LAURENCIN CATO T, who serves as the Director of the company, sold 2,690 shares for $31.85 each. As a result, the insider received 85,676 and left with 15,169 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALKS now has a Market Capitalization of 4.47B and an Enterprise Value of 4.07B. As of this moment, Alkermes’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.94, and their Forward P/E ratio for the next fiscal year is 10.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69 while its Price-to-Book (P/B) ratio in mrq is 3.72. Its current Enterprise Value per Revenue stands at 2.45 whereas that against EBITDA is 7.84.
Stock Price History:
Over the past 52 weeks, ALKS has reached a high of $32.88, while it has fallen to a 52-week low of $20.46. The 50-Day Moving Average of the stock is 28.42, while the 200-Day Moving Average is calculated to be 28.22.
Shares Statistics:
Over the past 3-months, ALKS traded about 1.87M shares per day on average, while over the past 10 days, ALKS traded about 2.68M shares per day. A total of 166.98M shares are outstanding, with a floating share count of 164.62M. Insiders hold about 1.47% of the company’s shares, while institutions hold 106.26% stake in the company. Shares short for ALKS as of Feb 29, 2024 were 13.02M with a Short Ratio of 6.96, compared to 11.66M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.79% and a Short% of Float of 8.89%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $0.69 for the current quarter, with a high estimate of $0.92 and a low estimate of $0.58, while EPS last year was $0.01. The consensus estimate for the next quarter is $0.79, with high estimates of $0.95 and low estimates of $0.71.
Analysts are recommending an EPS of between $2.85 and $2.35 for the fiscal current year, implying an average EPS of $2.73. EPS for the following year is $2.7, with 7 analysts recommending between $3.26 and $2.35.
Revenue Estimates
8 analysts predict $377.5M in revenue for the current quarter. It ranges from a high estimate of $415.01M to a low estimate of $366M. As of the current estimate, Alkermes plc’s year-ago sales were $287.6M, an estimated increase of 31.30% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $393.94M, a decrease of -36.20% less than the figure of $31.30% in the same quarter last year. There is a high estimate of $426.01M for the next quarter, whereas the lowest estimate is $384.96M.
A total of 12 analysts have provided revenue estimates for ALKS’s current fiscal year. The highest revenue estimate was $1.56B, while the lowest revenue estimate was $1.48B, resulting in an average revenue estimate of $1.53B. In the same quarter a year ago, actual revenue was $1.66B, down -8.10% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $1.54B in the next fiscal year. The high estimate is $1.74B and the low estimate is $1.43B. The average revenue growth estimate for next year is up 0.80% from the average revenue estimate for this year.
